Core Viewpoint - The company, EPS Creation Technology (03860.HK), has signed a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Co., Ltd, which is seen as a strategic investment to enhance its involvement in the biopharmaceutical sector and create long-term value [1] Group 1: Acquisition Details - The acquisition involves China Gene Engineering Co., Ltd, a company registered in Hong Kong, which holds approximately 67.68% of Shanghai Huaxin Biological High-Tech Co., Ltd [1] - The acquisition is expected to be recognized as an investment in an associate company in the consolidated financial statements of the group upon completion [1] Group 2: Strategic Importance - The board believes that this acquisition presents an excellent opportunity for the group to expand its operational involvement with China Gene Group [1] - The investment aligns with the group's existing business in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services, thereby complementing its current operations [1]
EPS创健科技(03860.HK)拟收购中国基因工程16.23%股权